Niagen Bioscience (OCD1) Price & Analysis

Compare

0 Followers

OCD1 Stock Chart & Stats

€6.05

€0.05(0.98%)

At close: Jan 08 4:00 PM EST

€6.05

€0.05(0.98%)

Day’s Range― - ―

52-Week Range€3.12 - €12.40

Previous CloseN/A

Volume0.00

Average Volume (3M)5.00

Market Cap

$493.84M

Enterprise Value€1.19B

Total Cash (Recent Filing)$60.32M

Total Debt (Recent Filing)$3.29M

Price to Earnings (P/E)―

Beta1.05

Next Earnings

Nov 04, 2025

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.03

Shares Outstanding79,752,960

10 Day Avg. Volume0

30 Day Avg. Volume5

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap2.40

Enterprise Value/Revenue10.19

Enterprise Value/Gross Profit16.02

Enterprise Value/Ebitda65.44

Forecast

1Y Price Target

$13.35

Price Target Upside120.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial PerformanceNiagen Bioscience's revenue and earnings have exceeded expectations, leading to an increased price target.

Product EfficacyNiagen's flagship ingredient NR has been extensively studied with over 40 peer-reviewed clinical publications, indicating strong scientific support.

Sales GrowthThe company's flagship nicotinamide riboside brand, TRU NIAGEN, delivered strong sales growth of 22%.

Bears Say

CompetitionThe FDA decision that NMN can be used in supplements could lead to more NMN products and increased competition for Niagen Bioscience.

Market RisksRisks include slower-than-projected U.S. sales growth, unfavorable clinical data, and adverse legal decisions.

Niagen Bioscience News

Fifth Third buying Comerica, AMD gets OpenAI boost: Morning Buzz

The major averages were mixed at midday, with the Dow the lone index in the red as the...

16d ago

Niagen Bioscience raises FY25 revenue view to up 25%-30% from up 22%-27%

“Elevating NAD+ is critical for health, especially as we age, and greater attention to this important area of...

16d ago

NAGE

Niagen Bioscience’s Niagen IV, injections now available at iCRYO clinics

Niagen Bioscience (NAGE) announced that its pharmaceutical-grade Niagen Plus products, Niagen IV and injections, are now offered at...

21d ago

NAGE

Niagen Bioscience Raises 2025 Sales Outlook Amid FDA Ruling

The latest update is out from Niagen Bioscience ( ($NAGE) ). On October 6, 2025, Niagen Bioscience announced...

15d ago

NAGE

Promising Growth and Innovation Drive Buy Rating for Niagen Bioscience

Canaccord Genuity analyst Susan Anderson has maintained their bullish stance on NAGE stock, giving a Buy rating yesterday....

2M ago

NAGE

Niagen Bioscience price target raised to $12 from $11 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Niagen Bioscience (NAGE) to $12 from $11 and keeps a...

2M ago

NAGE

Niagen Bioscience’s Robust Growth and Strategic Initiatives Drive Buy Rating

Canaccord Genuity analyst Susan Anderson has maintained their bullish stance on NAGE stock, giving a Buy rating today....

3M ago

NAGE

Niagen Bioscience Reports Strong Q2 Growth and Outlook

ChromaDex Corporation ( ($NAGE) ) has released its Q2 earnings. Here is a breakdown of the information ChromaDex...

3M ago

NAGE

Niagen Bioscience Reports Strong Q2 Sales Growth

Niagen Bioscience ( ($NAGE) ) has provided an update. On August 6, 2025, Niagen Bioscience reported a 37%...

3M ago

NAGE

Niagen Bioscience reports Q2 EPS 4c, consensus 1c

Reports Q2 revenue $31.1M, consensus $28.31M. “We delivered an excellent second quarter, with $31.1 million in net sales,...

3M ago

NAGE

Niagen Bioscience: Promising Clinical Results and Strategic IP Acquisitions Drive Buy Rating

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on NAGE stock, giving a Buy rating on...

3M ago

NAGE

Niagen Bioscience Subsidiary Signs Supply Agreement

Niagen Bioscience ( ($NAGE) ) just unveiled an announcement. On July 25, 2025, ChromaDex, Inc., a subsidiary of...

3M ago

NAGE

Niagen Bioscience licenses potential Parkinson’s therapy

Niagen Bioscience (NAGE) announced it has entered into a worldwide exclusive commercial license agreement with Haukeland University Hospital...

4M ago

NAGE

Niagen Bioscience Approves Equity Plan Amendment

Niagen Bioscience ( ($NAGE) ) has issued an update. At the Annual Meeting of Stockholders on June 24,...

4M ago

NAGE

OCD1 FAQ

What was Niagen Bioscience’s price range in the past 12 months?

Niagen Bioscience lowest stock price was €3.12 and its highest was €12.40 in the past 12 months.

What is Niagen Bioscience’s market cap?

Niagen Bioscience’s market cap is $493.84M.

When is Niagen Bioscience’s upcoming earnings report date?

Niagen Bioscience’s upcoming earnings report date is Nov 04, 2025 which is in 13 days.

How were Niagen Bioscience’s earnings last quarter?

Niagen Bioscience released its earnings results on Aug 06, 2025. The company reported €0.034 earnings per share for the quarter, beating the consensus estimate of €0.008 by €0.027.

Is Niagen Bioscience overvalued?

According to Wall Street analysts Niagen Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Niagen Bioscience pay dividends?

Niagen Bioscience does not currently pay dividends.

What is Niagen Bioscience’s EPS estimate?

Niagen Bioscience’s EPS estimate is 0.02.

How many shares outstanding does Niagen Bioscience have?

Niagen Bioscience has 79,752,960 shares outstanding.

What happened to Niagen Bioscience’s price movement after its last earnings report?

Niagen Bioscience reported an EPS of €0.034 in its last earnings report, beating expectations of €0.008. Following the earnings report the stock price went up 6.329%.

Which hedge fund is a major shareholder of Niagen Bioscience?

Currently, no hedge funds are holding shares in DE:OCD1

Niagen Bioscience Stock Smart Score

Outperform

Fundamentals

Return on Equity

37.36%

Trailing 12-Months

Asset Growth

69.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Niagen Bioscience

Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.

Niagen Bioscience (OCD1) Earnings & Revenues

Historic Earnings Reports

OCD1 Company Deck

OCD1 Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call for Niagen Bioscience presented a robust performance with significant revenue growth, increased net income, and cash generation. The expansion of Niagen Plus and a strengthened patent portfolio were key positive aspects. However, the company faces regulatory challenges and market misconceptions that require ongoing attention.View all DE:OCD1 earnings summaries

OCD1 Stock 12 Month Forecast

Average Price Target

€13.35

▲(120.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","20":"€20","5.75":"€5.75","10.5":"€10.5","15.25":"€15.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19.75284896,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€19.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.354643536,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€13.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.618778624,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€9.62</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.75,10.5,15.25,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.15,8.119449920000001,9.08889984,10.05834976,11.027799680000001,11.9972496,12.96669952,13.936149440000001,14.90559936,15.87504928,16.8444992,17.813949120000004,18.78339904,{"y":19.75284896,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.15,7.627280272,8.104560544,8.581840816,9.059121088,9.53640136,10.013681632,10.490961903999999,10.968242176,11.445522447999998,11.92280272,12.400082991999998,12.877363264,{"y":13.354643536,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.15,7.3399060480000005,7.529812096000001,7.719718144000001,7.909624192000001,8.09953024,8.289436288000001,8.479342336,8.669248384000001,8.859154432,9.049060480000001,9.238966528,9.428872576,{"y":9.618778624,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >